Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (30)

Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis

Didier Trono, Laurence Gouzi Abrami, Julien Léonard Duc, Sandra Eloise Kjeldsen, Alexandre Coudray, Sagane Dind, Evaristo Jose Planet Letschert, Laia Simo Riudalbas

The treatment of colorectal cancer (CRC) is an unmet medical need in absence of early diagnosis. Here, upon characterizing cancer-specific transposable element-driven transpochimeric gene transcripts (TcGTs) produced by this tumor in the SYSCOL cohort, we ...

Nature Research2022

Regulation of Src tumor activity by its N-terminal intrinsically disordered region

Florence Armand, Romain Hamelin

The membrane-anchored Src tyrosine kinase is involved in numerous pathways and its deregulation is involved in human cancer. Our knowledge on Src regulation relies on crystallography, which revealed intramolecular interactions to control active Src conform ...

SPRINGERNATURE2022

AMP-activated Protein Kinase (AMPK): New molecular insights and novel downstream targets

Katyayanee Neopane

AMP-activated Protein Kinase (AMPK) is a central regulator of energy homeostasis and a promising drug target for metabolic disorders. It exists as complexes of three subunits, a catalytic alpha, and two regulatory beta and gamma subunits. The regulation of ...

EPFL2022

Experiencing virtual geographic environment in urban 3D participatory e-planning: A user perspective

Jens Ingensand, Thibaud Nicolas Chassin

The adoption of technology in urban participatory planning with tools such as Virtual Geographic Environments (VGE) promises a broader engagement of urban dwellers, which should ultimately lead to the creation of better cities. However, the authorities and ...

ELSEVIER2022

Rational design of protein switches: applications in synthetic biology and cancer immunotherapy

Sailan Shui

Synthetic biology aims to engineer cells as miniature biological devices to sense, process, and respond to exogenous stimuli. Protein switches are designed to sense and respond to various molecular queues in a fast and specific manner, which fits the requi ...

EPFL2022

Interactive Digital Engagement With Visual Artworks and Cultural Artefacts Enhances User Aesthetic Experiences in the Laboratory and Museum

Martin Vetterli, Loïc Arnaud Baboulaz, Christine Mohr, Pierre Gabioud

Digital technologies reshape the way we interact with our environment, including with artworks. Advanced computational imaging solutions allow having extremely high-resolution digital reproductions of artworks outside museums, presumably increasing artwork ...

TAYLOR & FRANCIS INC2022

Questioning Wizard of Oz: Effects of Revealing the Wizard behind the Robot

Pierre Dillenbourg, Pierre Pravin Oppliger, Jauwairia Nasir, Barbara Bruno

Wizard of Oz, a very commonly employed technique in human-robot interaction, faces the criticism of being deceptive as the humans interacting with the robot are told, if at all, only at the end of their interaction that there was in fact a human behind the ...

IEEE2022

Protein Engineering for Personalized therapy and diagnosis

Lixia Wei

Protein Engineering, especially protein post-translational modification (PTM), ex-tends proteomes in a more complex way than one can expect from analysis of their encod-ing genomes. It can activate or deactivate certain catalytic functions, add new desired ...

EPFL2022

Generating macrocyclic inhibitors of protein-protein interactions

Gontran Sangouard

Protein-protein interactions (PPIs) play important roles in many diseases and their modulation is an attractive strategy for developing new therapeutics. However, the relatively large and often flat binding surfaces of PPIs makes the development of inhibit ...

EPFL2022

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Oliver Hantschel

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome-positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common "gatekeeper" mutation T315I ...

SPRINGER2021

Page 2 sur 2